Browse > Article
http://dx.doi.org/10.7314/APJCP.2016.17.5.2351

Thailand Consensus on Helicobacter pylori Treatment 2015  

Mahachai, Varocha (Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital)
Vilaichone, Ratha-Korn (Department of Medicine, Thammasat University Hospital)
Pittayanon, Rapat (Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital)
Rojborwonwitaya, Jarin (Thonburi Hospital)
Leelakusolvong, Somchai (Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University)
Kositchaiwat, Chomsri (Department of Medicine, Ramathibodi Hospital, Mahidol University)
Mairiang, Pisaln (Department of Medicine, Faculty of Medicine, KhonKaen University)
Praisontarangkul, Ong-Ard (Department of Internal Medicine, Faculty of Medicine, Chiang Mai University)
Ovartlarnporn, Buncha (NKC institute of Gastroenterology and Hepatology, Songklanagarind Hosptial)
Sottisuporn, Jaksin (NKC institute of Gastroenterology and Hepatology, Songklanagarind Hosptial)
Pisespongsa, Pises (Department of Internal Medicine, Faculty of Medicine, Chiang Mai University)
Maneerattanaporn, Monthira (Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University)
Sony, Ravin (Department of Internal Medicine Lampang hospital)
Sirinthornpunya, Siam (Department of Medicine, Rajavithi Hospital)
Chaiyamahapurk, Orawan (Department of Medicine, Buddhachinaraj Hospital)
Wiwattanachang, Olarn (Udonthani Hospital)
Sansak, Inchaya (Udonthani Hospital)
Harnsomboon, Piyathida (Department of Internal Medicine Lampang hospital)
Chitapanarux, Taned (Department of Internal Medicine, Faculty of Medicine, Chiang Mai University)
Chuenrattanakul, Surapon (Department of Medicine, Phramongkutklao Hospital)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.17, no.5, 2016 , pp. 2351-2360 More about this Journal
Abstract
Management of Helicobacter pylori infection is an important aspect of many upper gastrointestinal tract diseases, such as chronic gastritis, peptic ulcer disease, gastric cancer and mucosa-associated lymphoid tissue (MALT) lymphoma. The Thailand Consensus on H. pylori treatment 2015 consisted of 22 national experts who took active roles, discussed all important clinical information and investigated clinical aspects in four workshops, focuising on: (1) Diagnosis (2) Treatment (3) Follow-up after eradication and (4) H. pylori infection and special conditions. Experts were invited to participate on the basis of their expertise and contribution to H. pylori works and/or consensus methodology. The results of each workshop were taken to a final consensus vote by all experts. Recommendations were developed from the best evidence and availability to guide clinicians in management of this specific infection associated with variety of clinical outcomes.
Keywords
Helicobacter pylori; infection; treatment; guidelines; Thailand 2015;
Citations & Related Records
Times Cited By KSCI : 3  (Citation Analysis)
연도 인용수 순위
1 Chung JW, Lee JH, Jung HY, et al (2011). Second-line Helicobacter pylori eradication: a randomized comparison of 1 week or 2 week bismuth-containing quadruple therapy. Helicobacter, 16, 289-94.   DOI
2 Chung SJ, Lim SH, Choi J, et al (2011). Helicobacter pylori serology inversely correlated with the risk and severity of reflux esophagitis in Helicobacter pylori endemic Area: A matched case-control study of 5,616 health check-up Koreans. J Neurogastroenterol Motil, 17, 267-73.   DOI
3 Correa P (1992). Human gastric carcinogenesis: a multistep and multifactorial process--first american cancer society award lecture on cancer epidemiology and prevention. Cancer Res, 52, 6735-40.
4 Correa P, Piazuelo MB, Wilson KT (2010). Pathology of gastric intestinal metaplasia: clinical implications. Am J Gastroenterol, 105, 493-8.   DOI
5 Crowe SE (2015). Indications and diagnostic tests for Helicobacter pylori infection. Up To Date. Literature review current through: Jul 2015. | This topic last updated: Mar 12, 2015.
6 Cutler AF, Elnagger M, Brooks E, et al (1998). Effect of standard and high dose ranitidine on [13C] urea breath test results. Am J Gastroenterol, 93, 1297-99.   DOI
7 Cutler AF, Prasad VM, Santogade P (1998). Four-year trends in Helicobacter pylori IgG serology following successful eradication. Am J Med, 105, 18.   DOI
8 de Vries AC, van Grieken NC, Looman CW, et al (2008). Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterol, 134, 945-52.   DOI
9 Di Caro S, Fini L, Daoud Y, et al (2012). Levofloxacin/amoxicillin-based schemes vs quadruple therapy for Helicobacter pylori eradication in second line: a systematic review. World J Gastroenterol, 18, 5669-78.   DOI
10 Dinis-Ribeiro M, Areia M, de Vries AC et al (2012). Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy, 44, 74-94.   DOI
11 Dinis-Ribeiro M, Lopes C, da Costa-Pereira A, et al (2004). A follow up model for patients with atrophic chronic gastritis and intestinal metaplasia. J Clin Pathol, 57, 177-82.   DOI
12 Federico A, Nardone G, Gravina AG, et al (2012). Efficacy of 5-day levofloxacin-containing concomitant therapy in eradication of Helicobacter pylori infection. Gastroenterol, 143, 55-61.   DOI
13 Fischbach L, Evans EL (2007). Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther, 26, 343-57.   DOI
14 Fischbach LA, Graham DY, Kramer JR, et al (2014). Association between Helicobacter pylori and Barrett's esophagus: a case-control study. Am J Gastroenterol, 109, 357-68.   DOI
15 Figura N, Crabtree JE, Dattilo M (1997). In-vitro activity of lansoprazole against Helicobacter pylori. J Antimicrob Chemother, 39, 585-90.   DOI
16 Ford AC, Delaney BC, Forman D, et al (2004). Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis. Am J Gastroenterol, 99, 1833-55.   DOI
17 Fuccio L, Zagari RM, Eusebi LH, et al (2009). Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann Intern Med, 151, 121-8.   DOI
18 Ford AC, Delaney BC, Forman D, et al (2006). Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane Database Syst Rev.
19 Ford AC, Forman D, Hunt RH, et al (2014). Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ, 348, 3174.   DOI
20 Franceschi FL, Cazzato A, et al (2007). A Role of probiotics in patients with Helicobacter pylori infection. Helicobacter, 12, 59-63.   DOI
21 Fukase K, Kato M, Kikuchi S, et al (2008). Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet, 372, 392-7.   DOI
22 Gatta L, Vakil N, Ricci C, et al (2004). Effect of proton pump inhibitors and antacid therapy on 13C-urea breath tests and stool test for Helicobacter pylori infection. Am J Gastroenterol, 99, 823-9.   DOI
23 Gisbert JP, Pajares JM (2005). Review article: C-urea breath test in the management of Helicobacter pylori infection: Review article. Diagnosis Liver Disease, 37, 899-906.   DOI
24 Gisbert JP, Barrio J, Modolell I, et al (2015). Helicobacter pylori first-line and rescue treatment in the presence of penicillin allergy. Dig Dis Sci, 60, 458-64.   DOI
25 Gisbert JP, Khorrami S, Carballo F, et al (2004). H. pylori eradication therapy vs. antisecretory non-eradication therapy (with or without long-term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer. Cochrane Database Syst Rev. 4062.
26 Gisbert JP, Gisbert JL, Marcos S, et al (2005). Helicobacter pylori first-line treatment and rescue options in patients allergic to penicillin. Aliment Pharmacol Ther, 22, 1041-6.   DOI
27 Howden CW, Hunt RH (1998). Guidelines for the management of Helicobacter pylori infection. ad hoc committee on practice parameters of the american college of gastroenterology. Am J Gastroenterol, 93, 2330-8.   DOI
28 Graham DY, Opekun AR, Hammoud F, et al (2003). Studies regarding the mechanism of false negative urea breath tests with proton pump inhibitors. Am J Gastroenterol, 98, 1005-9.   DOI
29 Hackelsberger A, Schultze V, Gunther T, et al (1997). Helicobacter pylori prevalence in reflux esophagitis: A case control study (abstract). Gastroenterol, 112, A137.
30 Higuchi K, Fujiwara Y, Tominaga K, et al (2003). Is eradication sufficient to heal gastric ulcers in patients infected with Helicobacter pylori? A randomized, controlled, prospective study. Aliment Pharmacol Ther, 17, 111-17.
31 Hong SS, Jung HY, Choi KD, et al (2006). A prospective analysis of low-grade gastric malt lymphoma after Helicobacter pylori eradication. Helicobacter, 11, 569-73.   DOI
32 Huang JQ, Sridhar S, Hunt RH (2002). Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet, 359, 14-22.   DOI
33 Graham DY, Klein PD (2000). Accurate diagnosis of Helicobacter pylori. 13C-urea breath test. Gastroenterol Clin North Am, 29, 885-93.   DOI
34 Gisbert JP, Pajares JM (2005). Systematic review and meta-analysis: is 1-week proton pump inhibitor-based triple therapy sufficient to heal peptic ulcer? Aliment Pharmacol Ther, 21, 795-804.   DOI
35 Goddard AF, Badreldin R, Pritchard DM et al (2010). The management of gastric polyps. Gut, 59, 1270-6.   DOI
36 Graham DY, Hammoud F, El-Zimaity HM, et al (2003). Meta-analysis: proton pump inhibitor or H2-receptor antagonist for Helicobacter pylori eradication. Aliment Pharmacol Ther, 17, 1229-36.   DOI
37 Kanizaj TF, Kunac N (2014). Helicobacter pylori: future perspectives in therapy reflecting three decades of experience. World J Gastroenterol, 20, 699-705.   DOI
38 Jainan W, Vilaichone RK (2014). Effects of the CYP2C19 genetic polymorphism on gastritis, peptic ulcer disease, peptic ulcer bleeding and gastric cancer. Asian Pac J Cancer Prev, 15, 10957-60.
39 Jeajaroonwong W (2003). PPI-based Triple Therapy for Helicobacter pylori Eradication at NaKhonpathom Hospital. Reg 4-5 Med J, 31, 14-8.
40 Jyotheeswaran S, Shah AN, Jin HO, et al (1998). Prevalence of Helicobacter pylori in peptic ulcer patients in greater Rochester, NY: is empirical triple therapy justified? Am J Gastroenterol, 93, 574.   DOI
41 Kato M, Asaka M, Ono S, et al (2007). Eradication of Helicobacter pylori for primary gastric cancer and secondary gastric cancer after endoscopic mucosal resection. J Gastroenterol, 42, 16-20.
42 Kim SG, Jung HK, Lee HL, et al (2014). Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition. J Gastroenterol Hepatol, 29, 1371-86.   DOI
43 Kongchayanun C, Vilaichone R, Pornthisarn B, et al (2012). Pilot studies to identify the optimum duration of concomitant helicobacter pylori eradication therapy in Thailand. Helicobacter, 17, 282-5.   DOI
44 Kullavanijaya P, Thong-Ngam D, Hanvivatvong O, et al (2004). Analysis of eight different methods for the detection of Helicobacter pylori infection in patients with dyspepsia. J Gastroenterol Hepatol, 19, 1392-6.   DOI
45 Laine L, Estrada R, Trujillo M, et al (1998). Effect of proton-pump inhibitor therapy on diagnostic testing for Helicobacter pylori. Ann Intern Med, 129, 547.   DOI
46 Leodoltor A, Dominguez-Munoz JE, von Arnim U, et al (1999). Validity of a modified 13 C-urea breath test for pre-and posttreatment diagnosis of Helicobacter pylori in the routine clinical setting. Am J Gastroenterol, 94, 2100-4.   DOI
47 Laine L, Hopkins RJ, Girardi LS (1998). Has the impact of Helicobacter pylori therapy on ulcer recurrence in the United States been overstated? A meta-analysis of rigorously designed trials. Am J Gastroenterol, 93, 1409.
48 Lamouliatte H, Megraud F, Delchier J, et al (2003). Second-line treatment for failure toeradicate H. pylori: a randomized trial comparing four treatment strategies. Aliment Pharmacol Ther, 18, 791-7.   DOI
49 Lam SK, Ching CK, Lai KC, et al (1997). Does treatment of Helicobacter pylori with antibiotics alone heal duodenal ulcer? A randomized double blind placebo controlled study. Gut, 41, 43.   DOI
50 Leodolter A, Kulig M, Brasch H, et al (2001). A meta-analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori-associated gastric or duodenal ulcer. Aliment Pharmacol Ther, 15, 1949.   DOI
51 Leung WK, Lin SR, Ching JY et al (2004). Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut, 53, 1244-9.   DOI
52 Loy CT, Irwig LM, Katelaris PH, et al (1996). Do commercial serological kits for Helicobacter pylori infection differ in accuracy? A meta-analysis. Am J Gastroenterol, 91, 1138-44.
53 Marzio L, Cellini L, Angelucci D (2003). Triple therapy for 7 days vs. triple therapy for 7 days plus omeprazole for 21 days in treatment of active duodenal ulcer with Helicobacter pylori infection. A double blind placebo controlled trial. Dig Liver Dis, 35, 20e3.
54 Mahachai V, Vilaichone RK (2011). Current status of Helicobacter pylori Infection in Thailand. Helicobacter Research, 15, 38-44.
55 Maehata Y, Nakamura S, Fujisawa K, et al (2012). Long-term effect of Helicobacter pylori eradication on the development of metachronous gastric cancer after endoscopic resection of early gastric cancer. Gastrointest Endosc, 75, 39-46.   DOI
56 Malfertheiner P, Megraud F, O'Morain CA, et al (2012). Management of Helicobacter pylori infection--the maastricht iv/ florence consensus report. Gut, 61, 646-64.   DOI
57 Moayyedi P (2011). Helicobacter pylori eradication for functional dyspepsia: what are we treating?: comment on "Helicobacter pylori eradication in functional dyspepsia". Arch Intern Med, 171, 1936-7.   DOI
58 Moayyedi P, Soo S, Deeks J, et al (2000). Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. Dyspepsia Review Group. BMJ, 321, 659-64.   DOI
59 Lundell L, Havu N, Miettinen P, et al (2006). Changes of gastric mucosal architecture during long-term omeprazole therapy: results of a randomized clinical trial. Aliment Pharmacol Ther, 23, 639-47.   DOI
60 Lundell L, Vieth M, Gibson F, et al (2015). Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology. Aliment Pharmacol Ther, 42, 649-63.   DOI
61 Moayyedi P, Wason C, Peacock R, et al (2000). Changing patterns of Helicobacter pylori gastritis in long-standing acid suppression. Helicobacter, 5, 2016-14.
62 O'Connor HJ (1999). Review article: Helicobacter pylori and gastro-oesophageal reflux disease-clinical implications and management. Aliment Pharmacol Ther, 13, 117-27.   DOI
63 Patel SK, Pratap CB, Jain AK, et al (2014). Diagnosis of Helicobacter pylori: what should be the gold standard? World J Gastroenterol, 20, 12847-59.   DOI
64 Romano M, Cuomo A, Gravina AG, et al (2010). Empiric levofloxacin-containing vs clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomized trial. Gut, 59, 1465-70.   DOI
65 Prapitpaiboon H, Mahachai V, Vilaichone RK (2015). High Efficacy of Levofloxacin-Dexlansoprazole-Based Quadruple Therapy as a First Line Treatment for Helicobacter pylori Eradication in Thailand. Asian Pac J Cancer Prev, 16, 4353-6.   DOI
66 Prasertpetmanee S, Mahachai V, Vilaichone RK (2013). Improved efficacy of PPI - amoxicillin - clarithromycin triple therapy for H. pylori eradication in low clarithromycin resistance areas or for tailored therapy. Helicobacter, 18, 270-3.   DOI
67 Rokkas T, Sechopoulos P, Pistiolas D, et al (2010). Helicobacter pylori infection and gastric histology in first-degree relatives of gastric cancer patients: a meta-analysis. Eur J Gastroenterol Hepatol, 22, 1128-33.   DOI
68 Ruskone-Fourmestraux A, Fischbach W, Aleman BM, et al (2011). EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT. Gut, 60, 747-58.   DOI
69 Savarino V, Tracci D, Dulbecco P, et al (2001). Negative effect of ranitidine on the results of urea breath test for the diagnosis of Helicobacter pylori. Am J Gastroenterol, 96, 348-52.   DOI
70 Shirin H, Levine A, Shevah O, et al (2005). Eradication of Helicobacter pylori can be accurately confirmed 14 days after termination of triple therapy using a high-dose citric acid-based 13C urea breath test. Digestion, 71, 208-12.   DOI
71 Shirota T, Kusano M, Kawamura O, et al (1999). Helicobacter pylori infection correlates with severity of reflux esophagitis: with manometry findings. J Gastroenterol, 34, 553-9.   DOI
72 Sipponen P, Helske T, Jarvinen P et al (1994). Fall in the prevalence of chronic gastritis over 15 years: analysis of outpatient series in Finland from 1977, 1985, and 1992. Gut, 35, 1167-71.   DOI
73 Sirimontaporn N, Thong-Ngam D, Tumwasorn S, et al (2010). Ten-day Sequential Therapy of Helicobacter pylori infection in Thailand. Am J Gastroenterol, 105, 1071-5.   DOI
74 Smith SM, O'Morain C, McNamara D (2014). Antimicrobial susceptibility testing for Helicobacter pylori in times of increasing antibiotic resistance. World J Gastroenterol, 20, 9912-21.   DOI
75 Song H, Ekheden IG, Zheng Z, et al (2015). Incidence of gastric cancer among patients with gastric precancerous lesions: observational cohort study in a low risk Western population. BMJ, 351, 3867.
76 Srinarong C, Mahachai V, Vilaichone RK (2014). High efficacy of 14-day standard triple therapy plus bismuth with probiotic supplement for H. pylori eradication in low clarithromycin resistance areas. Asian Pac J Cancer Prev, 15, 9909-13.   DOI
77 Stathis A, Chini C, Bertoni F, et al (2009). Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type. Ann Oncol, 20, 1086-93.   DOI
78 Schenk BE, Kuipers EJ, Nelis GF, et al (2000). Effect of Helicobacter pylori eradication on chronic gastritis during omeprazole therapy. Gut, 46, 615-21.   DOI
79 Perri F, Manes G, Neri M, et al (2002). Helicobacter pylori antigen stool test and 13C-urea breath test in patients after eradication treatments. Am J Gastroenterol, 97, 2756.   DOI
80 Pittayanon R, Vilaichone RK, Lee GH, et al (2015). Influences of duration of treatment, CYP2C19 genotyping, interleukin-1 polymorphisms and antibiotic resistant strains in Helicobacter pylori eradication rates. digestive disease week (DDW), Washinton DC, USA (Abstract).
81 Uemura N, Okamoto S, Yamamoto S, et al (2001). Helicobacter pylori infection and the development of gastric cancer. N Engl J Med, 345, 784-9.   DOI
82 Sugano K, Tack J, Kuipers EJ, et al (2015). Kyoto global consensus report on Helicobacter pylori gastritis. Gut, 64, 1353-67.   DOI
83 Tan J, Wang Y, Sun X, et al (2015). The effect of Helicobacter pylori eradication therapy on the development of gastroesophageal reflux disease. Am J Med Sci, 349, 364-71.   DOI
84 Thailand Consensus for the management of Dyspepsia and Helicobacter pylori 2010 issued by The Gastroenterology Association of Thailand, Krungthep Vechasarn publishing, Bangkok, Thailand
85 Vaira D, Malfertheiner P, Megraud F, et al (1999). Diagnosis of Helicobacter pylori infection with a new non-invasive antigen-based assay. HpSA European study group. Lancet, 354, 30-3.   DOI
86 Vakil N, Hahn B, McSorley D (2000). Recurrent symptoms and gastroesophageal reflux disease in patients with duodenal ulcer treated for Helicobacter pylori infection. Aliment Pharmacol Ther, 14, 45-51.   DOI
87 van Zanten SV, van der Knoop B (2008). Gastric ulcer treatment: cure of Helicobacter pylori infection without subsequent acid-suppressive therapy: is it effective? Eur J Gastroenterol Hepatol, 20, 489-91.   DOI
88 Wang C, Yuan Y, Hunt RH (2009). Helicobacter pylori infection and Barrett's esophagus: a systematic review and meta-analysis. Am J Gastroenterol, 104, 492-500.   DOI
89 Wang J, Xu L, Shi R, et al (2011). Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication: a meta-analysis. Digestion, 83, 253-60.   DOI
90 Wilcox MH, Dent TH, Hunter JO, et al (1996). Accuracy of serology for the diagnosis of Helicobacter pylori infection-a comparison of eight kits. J Clin Pathol, 49, 373-6.   DOI
91 Varocha M, Sirimontaporn N, Thong-Ngam D, et al (2011). Sequential therapy in clarithromycin-sensitive and resistant Helicobacter pylori based on polymerase chain reaction molecular test. J Gastroenterol Hepatol, 26, 825-8.   DOI
92 Vilaichone RK, Mahachai V, Graham DY (2006). Helicobacter pylori: Diagnosis and management. Gastroenterol Clin North Am, 35, 229-47.   DOI
93 Vergara M, Catalan M, Gisbert JP, et al (2005). Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther
94 Zhang MM, Qian W, Qin YY, et al (2015). Probiotics in Helicobacter pylori eradication therapy: a systematic review and meta-analysis. World J Gastroenterol, 21, 4345-57.   DOI
95 Wong BC, Lam SK, Wong WM, et al (2004). Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA, 291, 187-94.   DOI
96 Wotherspoon AC, Doglioni C, Diss TC, et al (1993). Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet, 342, 575-7.   DOI
97 Zagari RM, Romano M, Ojetti V, et al (2015). Guidelines for the management of Helicobacter pylori infection in Italy: the III working group consensus report 2015. Dig Liver Dis, 47, 903-12.   DOI
98 Zullo A, Hassan C, Andriani A, et al (2009). Eradication therapy for Helicobacter pylori in patients with gastric MALT lymphoma: a pooled data analysis. Am J Gastroenterol, 104, 1932-7.   DOI
99 Asaka M, Kato M, Graham DY (2010). Prevention of gastric cancer by Helicobacter pylori eradication. Intern Med, 49, 633-6.   DOI
100 Arkkila PE, Seppala K, Kosunen TU, et al (2005). Helicobacter pylori eradication as the sole treatment for gastric and duodenal ulcers. Eur J Gastroenterol Hepatol, 17, 93-101.   DOI
101 Asaka M, Sugiyama T, Nobuta A, et al (2001). Atrophic gastritis and intestinal metaplasia in Japan: results of a large multicenter study. Helicobacter, 6, 294-9.   DOI
102 Bravo LE, Realpe JL, Campo C, et al (1999). Effects of acid suppression and bismuth medications on the performance of diagnostic tests for Helicobacter pylori infection. Am J Gastroenterol, 94, 2380-3.   DOI
103 Burucoa C, Delchier JC, Courillon-Mallet A, et al (2013). Comparative evaluation of 29 commercial Helicobacter pylori serological kits. Helicobacter, 18, 169-79.   DOI
104 Chen HN, Wang Z, Li X et al (2016). Helicobacter pylori eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia: evidence from a meta-analysis. Gastric Cancer.
105 Cammarota G, Martino A, Pirozza G, et al (2004). High efficacy of 1-week doxycyline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for H. pylori infection. Aliment Pharmacol Ther, 19, 789-95.   DOI
106 Chan FK, Ching JY, Suen BY, et al (2013). Effects of Helicobacter pylori infection on long-term risk of peptic ulcer bleeding in low-dose aspirin users. Gastroenterol, 144, 528-35.   DOI
107 Chan FK, Sung JJ, Chung SC, et al (1997). Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet, 350, 975-9.   DOI
108 Abraham NS, Hlatky MA, Antman EM, et al (2010). ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol, 105, 2533-49.   DOI
109 Alahdab YO, Kalayci C (2014). Helicobacter pylori : Management in 2013. World J Gastroenterol, 20, 5302-7.   DOI
110 Chan FK, To KF, Wu JC, et al (2002). Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet, 359, 9-13.   DOI
111 Chen LT, Lin JT, Tai JJ, et al (2005). Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma. J Natl Cancer Inst, 97, 1345-53.   DOI
112 Chey WD, Wong BC (2007). Practice parameters committee of the american college of gastroenterology. american college of gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol, 102, 1808.   DOI
113 Chitapanarux T, Thongsawat S, et al (2015). Effect of Bifidobacterium longum on-based triple PPI therapy for eradication of Helicobacter pylori. Functional Foods, 13, 289-94.   DOI